- |||||||||| M102 / Aclipse Therap, The University of Sheffield
M102 A multi-target drug suitable for personalised medicine approaches in ALS (Event Halle, Messe Basel, Ground Floor) - Nov 7, 2023 - Abstract #ALSMND2023ALS_MND_488;
Using a combination of immunostaining and immunoblotting techniques, we confirmed that this drug has a modest effect in inducing activation of nuclear factor erythroid 2-related factor 2 (NRF2) and heat shock factor 1 (HSF1) signalling pathways in patient-derived neurons (n = 6), but a much higher effect activating these pathways in patient-derived astrocytes (n = 3). Furthermore, our data suggest M102 can reduce TDP43 proteinopathy in patient-derived astrocytes, by reducing the levels of TDP43 fragments and increasing full length protein (n = 3).
|
